+ All Categories
Home > Documents > Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach...

Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach...

Date post: 20-Jan-2016
Category:
Upload: shana-benson
View: 217 times
Download: 2 times
Share this document with a friend
Popular Tags:
20
Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University of Florida College of Medicine Division of Orthopaedic Oncology
Transcript
Page 1: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Quantifying the Morbidity of the Unplanned Sarcoma

ExcisionRobert Tamurian, Robert Zlotecki, Zach Adler,

Mark Scarborough, and Parker Gibbs

University of Florida College of MedicineDivision of Orthopaedic Oncology

Page 2: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

The Unplanned Excision

• The excision of a soft tissue mass not thought to be malignant, that upon subsequent pathologic examination results in the utterance: “whoops, that’s a sarcoma”

• Standard of care: Wide excision of the tumor bed +/- adjuvant therapy

• ~50% have residual disease in re-excision specimen

Giuliano and Eilber JCO 1985

Page 3: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

UF Protocol

• MRI to best determine extent of bed and identify potential gross residual disease

• Wide re-excision of tumor bed

• Adjuvant radiotherapy for high risk tumor bed (most)– Tumor in re-excision bed– Large hematoma– Extensive edema

Page 4: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.
Page 5: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Wide Re-Excision

• Numerous Articles

• The unplanned sarcoma excision has no significant effect on survival if wide re-excision is performed

• Local recurrence may be increased

• Morbidity is only obliquely mentioned– Difficult to assess– Difficult to identify a matched cohort

Page 6: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Goal

• Attempt to quantify the morbidity to a patient who has undergone a wide re-excision following “whoops surgery”

• Compare what had to be done to what could have been done had we seen them first

• Each patient serves as his/her own comparison case

Page 7: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

What to Measure?

• Volume of Tissue Resected upon Re-Excision

– Larger resection volume directly associated with increased wound complications and need for soft tissue coverage

Geller et. al. CORR 2007

Page 8: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Adjuvant Therapy

• Radiation Field Size Key determinant of long term adverse sequelae

• Edema• Subcutaneous Fibrosis• Joint stiffness

– These three variables most strongly associated with decreased functional outcome scores

Davis et. al. Radiother Oncol 2005

Page 9: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Study

• Retrospective review of our prospectively collected database to identify patients having had an unplanned excision of a sarcoma and subsequently referred for definitive management.

• 55 patients identified in the contemporary period from 1995-2007 with adequate data

Page 10: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Patients

• M:F 1.2:1

• Mean age 55 (range 17-56)

• Avg F/U 55mos (range 6-150 mos)– Oncologic data only on those with 2yr f/u

Page 11: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Tumors

• MFH most common histology (55%)• Avg tumor size 34.5 cm3 • Hi Grade 65%• Low Grade 35%• Superficial 64%• Deep 36%• Small (< 5cm) 60%• Large (> 5cm) 40%

Page 12: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Volume of Tissue Resected

Optimal resection volume (what we would have done) determined as original tumor volume plus one cm in all directions to simulate wide margin.

Tumor Bed resection volume (what had to be done) determined by direct measurement of pathologic specimen after re-excision of tumor bed

Tumor Bed Excision

Page 13: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Radiation Plan

Optimal Plan What Had to Be Done

Page 14: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Oncologic Outcome

• Overall Survival 89%

• Local Recurrence rate 21%

• Residual Disease in 44%– Increased risk of LR (p < 0.05)

Page 15: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

95 cm3

348 cm3

35 cm3

Optimal Resection

VS

Re-Excision Procedure

P< 0.01

Page 16: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Actualvs.

Optimal field area(p < 0.001)

362.4cm2

163.4 cm2

Actual radiation field size220% greater than Optimal

P < 0.001

Page 17: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Soft Tissue Coverage

STSG 57% 12%

Flap 26% 7%

Total 83% 19%

Re-Excision Primary Excision*

Contemporary unmatched cohort of 403STS managed primarily at UF

Page 18: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Morbidity

• By definition, at least one additional operative intervention

• Three times the Volume of Tissue (patient) Resected

• Twice the Radiation Field Size

• Marked Increase in Soft Tissue Coverage

Procedures

Page 19: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

Res Ipsa Loquitur

Page 20: Quantifying the Morbidity of the Unplanned Sarcoma Excision Robert Tamurian, Robert Zlotecki, Zach Adler, Mark Scarborough, and Parker Gibbs University.

www.ortho.ufl.edu


Recommended